Current role and future scope of upadacitinib in dermatology
Indian Journal of Skin Allergy · 18.03.2026 · 5 · 40-51
DOI: 10.25259/ijsa_80_2025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Skin Allergy, online erschienen am 18.03.2026. Verfasst von Farhat Fatima und 2 weiteren Autor:innen. Die Arbeit nennt 68 Literaturangaben.
Abstract (Originalsprache)
Upadacitinib, a selective Janus Kinase 1 (JAK1) inhibitor, has rapidly emerged as an important therapeutic option for a wide range of immune-mediated inflammatory conditions. Upadacitinib efficiently targets important pathways causing chronic inflammation by selectively blocking JAK1-dependent cytokine signaling. Clinical trials have demonstrated efficacy in atopic dermatitis (AD), hidradenitis suppurativa (HS), and psoriasis in cases of psoriatic arthritis. Real-world data reinforce these findings, and also in other dermatologic conditions such as vitiligo, lichen planus (LP), and alopecia areata (AA). Future scope includes biomarker-driven personalization, data comparison with next-generation biologics, long-term safety monitoring, and dose selection optimization to balance tolerability and efficacy across a range of patient populations.
Zitieren
APA
Fatima, F., Verma, S., & De, A. (2026). Current role and future scope of upadacitinib in dermatology. Indian Journal of Skin Allergy, 5, 40-51. https://doi.org/10.25259/ijsa_80_2025
Vancouver
Fatima F, Verma S, De A. Current role and future scope of upadacitinib in dermatology. Indian Journal of Skin Allergy. 2026;5:40-51. doi:10.25259/ijsa_80_2025
BibTeX
@article{Fatima2026,
author = {Fatima, Farhat and Verma, Shailja and De, Abhishek},
title = {Current role and future scope of upadacitinib in dermatology},
journal = {Indian Journal of Skin Allergy},
year = {2026},
volume = {5},
pages = {40--51},
doi = {10.25259/ijsa_80_2025}
}
EUVIMED